In this third of a four-part podcast series, we discuss the science, regulatory framework, and commercial transactions considerations of a COVID-19 vaccine. Michael Ward, MoFo partner and global head of the firm’s Life Sciences Group and Patent Group, discusses these issues among others with:
Otis Littlefield, senior of counsel in our Patent group: Why do we need vaccines? What are the general classes of vaccines? Where are we now with regard to vaccine development?
Bethany Hills, partner and head of MoFo’s FDA Regulatory + Life Sciences Compliance practice: What is the typical timeline for the development and regulatory approval of a vaccine? What is involved in the process? How does the FDA regulate vaccines under normal circumstances?
Rufus Pichler, partner in MoFo’s Commercial Life Sciences Transactions + Licensing Group and in the firm’s Technology Transactions practice: What are some of the unique commercial aspects to an accelerated vaccine development? How are companies assessing risk as they scale up their operations? What is the open COVID patent pledge?